Answers are grounded in this paper and cite their sources.
Background/Objectives: Venous thromboembolism is common during neoadjuvant chemotherapy for advanced ovarian cancer, but when to start thromboprophylaxis is unclear. We evaluated the association between early prophylactic-dose low-molecular-weight heparin, started at diagnosis or before the first cycle, and venous thromboembolism during neoadjuvant chemotherapy. Methods: This retrospective single-center cohort study included all consecutive women with stage III–IV epithelial ovarian cancer diagnosed between September 2012 and January 2025 who received neoadjuvant chemotherapy. Patients with venous thromboembolism at diagnosis were excluded. The primary endpoint was confirmed venous thromboembolism from the first cycle until interval debulking surgery or, without surgery, until completion of planned neoadjuvant chemotherapy or day 120, whichever occurred first. Associations were explored with Firth-penalized logistic regression. Results: Of 201 patients who received neoadjuvant chemotherapy, 192 formed the analytic cohort; 148 (77.1%) received early prophylaxis. Primary endpoint events occurred in 7 patients (3.6%; six pulmonary embolisms) at a median of 3.1 weeks after diagnosis. Events occurred in 1 of 148 patients (0.7%) with early prophylaxis and 6 of 44 (13.6%) without it. In exploratory multivariable analysis, early prophylaxis remained associated with lower odds (adjusted odds ratio [OR] 0.08, 95% confidence interval [CI] 0.01–0.47). A Khorana score of 3 or higher was associated with higher, imprecisely estimated odds (adjusted OR 12.70, 95% CI 1.17–1722). No major or clinically relevant non-major bleeding was identified (0/148 with prophylaxis; 95% CI 0–2.46%). Conclusions: Early prophylactic-dose low-molecular-weight heparin was associated with fewer venous thromboembolic events during neoadjuvant chemotherapy. Because prophylaxis was not randomized and events were few, these hypothesis-generating findings require prospective validation.
No takes yet. Share an insight, caveat, or question.
Tuncer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: